Ohmiya, Japan

Yukinari Kumazawa


Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1987-1988

Loading Chart...
2 patents (USPTO):Explore Patents

Title: **Yukinari Kumazawa: Pioneering Innovator in Pharmaceutical Chemistry**

Introduction

Yukinari Kumazawa is an esteemed inventor hailing from Ohmiya, Japan. With two patents to his name, he has made significant contributions to the field of pharmaceutical chemistry, particularly in therapeutic agents for cardiovascular disorders and antitumor activities.

Latest Patents

Kumazawa's most recent inventions involve two groundbreaking patents. The first is a method for preparing unsymmetrical 1,4-dihydropyridine-3,5-dicarboxylic acid diesters. This process utilizes an organic acid anhydride activating agent to create compounds beneficial as therapeutic agents for cardiovascular disorders. The second patent focuses on novel benzo[α]phenazine derivatives, showcasing their antitumor activity in mammals. These compounds offer a promising avenue for cancer treatment, as they include various substitutions that enhance their efficacy.

Career Highlights

Yukinari Kumazawa is a key innovator at Taisho Pharmaceutical Co., Ltd., where he applies his expertise in pharmaceutical chemistry to develop novel therapeutic agents. His involvement in research and development has established him as a valuable asset in the pursuit of solutions for complex medical issues.

Collaborations

Throughout his career, Kumazawa has collaborated with notable professionals such as Kaoru Sota and Yoshimoto Nakashima. These partnerships foster a collaborative environment that enhances the potential for innovation and strengthens the development of new therapeutic solutions in the pharmaceutical industry.

Conclusion

Yukinari Kumazawa's contributions to pharmaceutical chemistry, particularly through his patents, underline his commitment to advancing medical science. With a focus on developing potent therapeutic agents, his work continues to influence the landscape of cardiovascular and cancer treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…